Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Subsequent Events

Subsequent Events	12 Months Ended
Mar. 31, 2024
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	Note 19 — Subsequent Events On April 18, 2024 the Company granted 213,000 stock options to certain employees and directors with an exercise price of $0.68 and a three year vesting period. On June 7, 2024, the Company sold 391,017 shares at an average price of $1.9931 for net proceeds of $754,511 utilizing its At-the-Market Offering Agreement which was filed as a 6-K on January 22, 2024.

Subsequent Events

12 Months Ended

Mar. 31, 2024

Disclosure of non-adjusting events after reporting period [abstract]

Subsequent Events

Note 19 — Subsequent Events

On April 18, 2024 the Company granted 213,000 stock options to certain employees and directors with an exercise price of $0.68 and a three year vesting period.

On June 7, 2024, the Company sold 391,017 shares at an average price of $1.9931 for net proceeds of $754,511 utilizing its At-the-Market Offering Agreement which was filed as a 6-K on January 22, 2024.